194 related articles for article (PubMed ID: 38043492)
1. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
3. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
4. KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.
Crisman E; Duarte P; Dauden E; Cuadrado A; Rodríguez-Franco MI; López MG; León R
Med Res Rev; 2023 Jan; 43(1):237-287. PubMed ID: 36086898
[TBL] [Abstract][Full Text] [Related]
5. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
6. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.
Brennan MS; Matos MF; Li B; Hronowski X; Gao B; Juhasz P; Rhodes KJ; Scannevin RH
PLoS One; 2015; 10(3):e0120254. PubMed ID: 25793262
[TBL] [Abstract][Full Text] [Related]
7. The KEAP1-NRF2 System and Neurodegenerative Diseases.
Uruno A; Yamamoto M
Antioxid Redox Signal; 2023 May; 38(13-15):974-988. PubMed ID: 36930785
[No Abstract] [Full Text] [Related]
8. Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present).
Zhou H; Wang Y; You Q; Jiang Z
Expert Opin Ther Pat; 2020 Mar; 30(3):209-225. PubMed ID: 31922884
[No Abstract] [Full Text] [Related]
9. Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary.
Akino N; Wada-Hiraike O; Isono W; Terao H; Honjo H; Miyamoto Y; Tanikawa M; Sone K; Hirano M; Harada M; Hirata T; Hirota Y; Koga K; Oda K; Fujii T; Osuga Y
Reprod Biol Endocrinol; 2019 Feb; 17(1):23. PubMed ID: 30760288
[TBL] [Abstract][Full Text] [Related]
10. Electrophiles Against (Skin) Diseases: More Than Nrf2.
Hennig P; Fenini G; Di Filippo M; Beer HD
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32053878
[TBL] [Abstract][Full Text] [Related]
11. The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies.
Manai F; Govoni S; Amadio M
Cells; 2022 Dec; 11(24):. PubMed ID: 36552824
[TBL] [Abstract][Full Text] [Related]
12. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
14. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
15. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
Geertsema S; Bourgonje AR; Fagundes RR; Gacesa R; Weersma RK; van Goor H; Mann GE; Dijkstra G; Faber KN
Trends Mol Med; 2023 Oct; 29(10):830-842. PubMed ID: 37558549
[TBL] [Abstract][Full Text] [Related]
16. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer.
Xie T; Zahid H; Ali AR; Joyce R; Yang G; Winz C; Le Y; Zhou R; Furmanski P; Hu L; Suh N
Toxicol Appl Pharmacol; 2023 Feb; 460():116375. PubMed ID: 36634873
[TBL] [Abstract][Full Text] [Related]
18. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the modification of Kelch-like ECH-associated protein 1 by different fumarates.
Qu L; Guo M; Zhang H; Chen X; Wei H; Jiang L; Li J; Chen Z; Dai S; Chen Y
Biochem Biophys Res Commun; 2022 May; 605():9-15. PubMed ID: 35306364
[TBL] [Abstract][Full Text] [Related]
20. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.
Deshmukh P; Unni S; Krishnappa G; Padmanabhan B
Biophys Rev; 2017 Feb; 9(1):41-56. PubMed ID: 28510041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
